Ftse Mib
33.746,66
-1,60%
DAX
17.932,17
-1,10%
S&P 500
5.035,69
-1,57%
NASDAQ Composite
15.657,82
-2,04%
Bitcoin
60.440,56
-5,32%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NYSE Invitae Corporation (NVTA) Invitae Corporation (NVTA) Notizie

Invitae Corporation

NVTA
0,0891
0,00 (0,00%)
Dopo l'orario di negoziazione
Ultimo aggiornamento: 02:00:00
Dati in Delay di 15 minuti
Borsa: NYSE
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
06/3/202414:31EDGAR2Form 8-K - Current report
06/2/202423:07EDGAR2Form 8-K - Current report
30/1/202413:00PRNUSInvitae Partners with BridgeBio Pharma to Harness Genetic..
29/1/202422:01EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
24/1/202422:34EDGAR2Form 8-K/A - Current report: [Amend]
22/1/202413:05EDGAR2Form 8-K - Current report
22/1/202413:00PRNUSInvitae Completes Sale of Reproductive Health Assets to..
18/1/202422:10EDGAR2Form 8-K - Current report
22/12/202303:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/12/202303:14EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/12/202322:29EDGAR2Form 8-K - Current report
13/12/202322:07PRNUSInvitae Divests Ciitizen Health Data Platform and Implements..
11/12/202322:41EDGAR2Form 8-K - Current report
17/11/202322:48EDGAR2Form 8-K - Current report
15/11/202322:22EDGAR2Form 8-K - Current report
15/11/202301:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
15/11/202301:55EDGAR2Form 3 - Initial statement of beneficial ownership of..
08/11/202322:36EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/11/202322:05EDGAR2Form 8-K - Current report
08/11/202322:01PRNUSInvitae Reports Third Quarter 2023 Financial Results
06/11/202322:00PRNUSInvitae Launches Enhanced Chemistry of MRD Test to Better..
01/11/202311:59PRNUSInvitae to Announce Third Quarter 2023 Financial Results on..
25/10/202317:00PRNUSLandmark Study Reveals Magnitude of Uncertain Results in..
21/10/202300:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/10/202322:38EDGAR2Form 8-K - Current report
19/10/202322:30PRNUSInvitae Appoints Dr. David Sholehvar as Chief Operating..
12/10/202322:15PRNUSRural Hospital System Demonstrates the Clinical Benefits of..
10/10/202322:30PRNUSInvitae to Present Data at the National Society of Genetic..
03/10/202318:07PRNUSInvitae's Common Hereditary Cancers Panel Receives FDA..
03/10/202303:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/10/202302:47EDGAR2Form 3 - Initial statement of beneficial ownership of..
30/9/202302:00DJNFDA Gives Marketing Authorization to Invitae Test for Cancer..
27/9/202322:29EDGAR2Form 8-K - Current report
26/9/202300:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/9/202322:30PRNUSInvitae Announces Appointment of Finance Veteran Ana Schrank..
22/9/202323:02EDGAR2Form 8-K - Current report
22/9/202322:30PRNUSInvitae Receives Notice of Non-Compliance with NYSE Minimum..
14/9/202323:21EDGAR2Form 3 - Initial statement of beneficial ownership of..
28/8/202322:02PRNUSInvitae Hires Industry Veteran Robert Guigley as Chief..
23/8/202314:12EDGAR2Form 8-K - Current report
15/8/202313:30PRNUSClinical Trial Results Support Genetic Testing of All..
14/8/202322:02PRNUSInvitae Announces Selection of Finance Executive Robert..
10/8/202322:03EDGAR2Form 424B2 - Prospectus [Rule 424(b)(2)]
10/8/202322:01EDGAR2Form 424B2 - Prospectus [Rule 424(b)(2)]
10/8/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
09/8/202315:22EDGAR2Form POS AM - Post-Effective amendments for registration..
09/8/202315:20EDGAR2Form POS AM - Post-Effective amendments for registration..
08/8/202322:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202322:09EDGAR2Form 8-K - Current report
08/8/202322:01PRNUSInvitae Reports Second Quarter 2023 Financial Results
Apertura: Min: Max:
Chiusura: 0,0891

La tua Cronologia

NYSE
NVTA
Invitae
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network